This article summarizes the genetic markers of human venous and arterial thrombotic disorders. For venous thromboembolism, a factor V mutation (Arg 506rGln) has the highest risk, followed by protein C, S and antithrombin III gene defects. By contrast, these genetic defects are not associated significantly with arterial atherothrombotic disorders. Instead, a glycoprotein IIIa polymorphism (Pro33 versus Leu 33) has been reported to be associated with myocardial infarction. Fibrinogen Bβ chain, factor VII, and plasminogen activator inhibitor-1 gene polymorphisms have been reported to influence the plasma levels of these factors and may indirectly be risk factors for arterial thrombotic disorders. Further studies will uncover additional genetic markers for thrombosis.
DahlbäckBCarlssonMSvenssonPJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein CProc Natl Acad Sci USA1993, 90:1004–1008.
2.
DahlbäckBHildebrandB: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor VProc Natl Acad Sci USA1994, 91:1396–1400.
3.
BertinaRMKoelemanBPCKosterTRosendaalFRDirvenRJde RondeH: Mutation in blood coagulation factor V associated with resistance to activated protein CNature1994, 369:64–67.
4.
DahlbäckB: Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolismBlood1995, 85:607–614.
5.
PlutzkyJHoskinsJHLongGLCrabtreeGR: Evolution and organization of the human protein C geneProc Natl Acad Sci USA1986, 83:546–560.
6.
LongGLMarshallAGardnerJCNaylorSL: Genes for vitamin K-dependent plasma protein C and S are located on chromosome 2 and 3, respectivelySomat Cell Mol Genet1988, 14:93–97.
7.
GriffinJHEvattBZimmermanTSKleissAJWidemanC: Deficiency of protein C in congenital thrombotic diseaseJ Clin Invest1981, 68:1370–1373.
8.
ReitsamPHPoortSRBernardiFGandrilleSLongGLSalaN: Protein C deficiency: A database of mutationsThromb Haemost1993, 69:77–84.
9.
MiletichJRShermanLBrozeGJJr: Absence of thrombosis in subjects with heterozygous protein C deficiencyN Engl J Med1987, 317:991–994.
10.
HirshJPrinsMHSamamaM: Approach to thrombophilia patients. In Hemostasis and Thrombosis, Third Edition. Edited by ColmanRWHirshJMarderVJSalzmanEW. Philadelphia: J.B. Lippincott Co.; 1994:1543–1561.
11.
Ploos van AmstelHKReitsmaPHvan der LogtCPEBertinaRM: Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS β: Duplication and silencing during primate evolutionBiochem1990, 29:7853–7861.
12.
WinterJHBennettBWattJLBrownTSan RománCSchinzelA: Genetic mapping of the structural gene for antithrombin III and Duffy Blood group and assignment of AT-III to 1 q22-q25Ann Hum Genet1982, 46:29–34.
13.
ProchowniKEVBockSCOrkinSH: Intron structure of the human AT-III gene differs from that of other members of the serine protease inhibitor superfamilyJ Biol Chem1985, 260:9608–9612.
LaneDAOldsRJBoisclairMChowdhuryVTheinSLCooperDN: Antithrombin III mutation database: First updateThromb Haemost1993, 70:361–369.
16.
TaitRCWalkerIDPerryDJCarrellRWIslamSIAMcCallF: Prevalence of antithrombin III deficiency in 4000 healthy blood donors [abstract]Thromb Haemost1991, 65:839.
17.
BrennerBZivelinALanirHGreengardJSGriffinJHSeligsohnU: Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficiency newborn with massive thrombosisBlood1996, 88:877–880.
18.
TripMDCatsVMvan CapelleFJVreekenJ: Platelet hyperaggregability and prognosis in survivors of myocardial infarctionN Engl J Med1990, 323:1549–1554.
19.
WuKK: Platelet activation mechanisms and markers in arterial thrombosisJ Intern Med1996, 239:17–34.
20.
MeadeTWMellowsSBrtozovicMMillerGJChakrabartiRRNorthWR: Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart StudyLancet1986, ii:533–537.
21.
WilhelmsenLSvardsuddKKorsan-BengtsenKLarssonBWelinLTibblinG: Fibrinogen as a risk factor for stroke and myocardial infractionN Engl J Med1984, 311:501–505.
22.
KannelWBWolfPACastelliWPD'AgostinoRB: Fibrinogen and risk of cardiovascular disease: The Framingham StudyJAMA1987, 258:1183–1186.
23.
HeinrichJBalleisenLSchulteHAssmannGvan de LooJ: Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy menArterioscler Thromb1994, 14:54–59.
24.
FolsomARWuKKShaharEDavisCE: Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosisArterioscler Thromb1993, 13:1829–1836.
25.
BrayPFBarshGRosaJPLuoXYMagenisEShumanMA: Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIaProc Natl Acad Sci USA1988, 85:8683–8687.
26.
NewmanPJValentinN: Human platelet alloantigens: Recent findings, new perspectivesThromb Haemost1995, 74:234–239.
27.
Weiss EbrayPFTaybackMSchulmanSPKicklerTSBeckerLCWeissJL: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosisN Engl J Med1996, 334:1090–1094.
28.
OlarsenBTeisbergPGedde-DahlTJr: Fibrinogen γ chain locus on chromosome 4 in manHum Genet1982, 61:24–26.
29.
KantJAFornaceAJJrSaxeDSimonMIMcBrideOWCrabtreeGR: Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. ProcNatl Acad Sci USA1985, 82:2344–2348.
30.
RoySOvertonORedmanC: Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chainsJ Biol Chem1994, 269:691–695.
31.
BaumannREHenschenAH: Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: Identification of polymorphisms at positions Aα312 and Bβ448Blood1993, 82:2117–2124.
32.
HumphriesSECookMDubowitzMStirlingYMeadeTW: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrationsLancet1987, i:1452–1455.
33.
ThomasAEGreenFRKelleherCHWilkesPJMeadeTWHumphriesSE: Variation in the promoter region of the β-fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokersThromb Haemost1991, 65:487–490.
34.
BehagueIPoirierONicaudVEvansAArveilerDLucG: β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM StudyCirculation1996, 93:440–449.
35.
O'HaraPJGrantFJHaldemanBA: Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulationProc Natl Acad Sci USA1987, 84:5158–5162.
36.
GreenFKelleherCWilkesHTempleAMeadeTHumphriesS: A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individualsArterioscler Thromb1991, 11:540–546.
37.
BernardiFMarchettiGPinottiMArcieriPBaronciniCPapacchiniM: Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasmaArterioscler Thromb Vas Biol1996, 16:72–76.
38.
SilveiraAGreenFKarpeFBlombäckMMHumphriesSHamstenA: Elevated levels of factor VII activity in the postprandial state: Effect of factor V arg-gln polymorphismThromb Haemost1994, 72:734–739.
39.
RosmaPJvan den BergEAKooistraT: Human PAI-1 geneJ Biol Chem1988, 263:9129–9141.
40.
HamstenAWimanBde FaireUBlombåckM: Increased plasma levels of a repaid inhibitor of PAI-1 in young survivors of myocardial infarctionN Engl J Med1985, 313:1557–1563.
41.
DawsonSHamstenAWimanBHennyAHumphriesSE: Genetic variation at the plasminogen activator inhibitor-I locus is associated with altered levels of PAI-1 activityAtheroscler Thromb1991, 11:183–190.
42.
ErikssonPKallinBVan 't HooftFMBåvenholmPHamstenA: Allele specific increase in basal transcription of the PAI-1 gene is associated with myocardial infarctionProc Natl Acad Sci USA1995, 92:1851–1855.
43.
YeSGreenFRScarabinPYNicaudVBaraLDawsonSJ: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM StudyThromb Haemost1995, 74:837–841.
44.
MalinowMR: Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosisCirculation1990, 81:2004–2006.
